September 30, 2025 — Leads & Copy — enGene Holdings Inc., a clinical-stage, non-viral genetic medicine company, has appointed Hussein Sweiti, M.D., MSc, as Chief Medical Officer, effective September 29, 2025.
Dr. Sweiti, a surgical oncologist and physician-scientist, brings over 15 years of experience in clinical practice, oncology clinical research, global drug development, regulatory submissions, and medical affairs. He previously served as Global Medical Head, Oncology Clinical Development at Johnson & Johnson (J&J), where he led clinical strategy and execution for the company’s bladder cancer portfolio, including FDA approval in high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
According to Ron Cooper, Chief Executive Officer of enGene, Dr. Sweiti’s expertise aligns with enGene’s transition to regulatory filing and commercialization after reaching target enrollment in detalimogene’s pivotal NMIBC clinical trial.
Dr. Sweiti received his medical degree from the University of Heidelberg and a Master of Science in Public Health from the University of Düsseldorf. He is board certified in surgical oncology and holds a Certification in Medical Oncology from the European Society for Medical Oncology (ESMO). He has authored over 70 peer-reviewed publications. As Chief Medical Officer, Dr. Sweiti will oversee enGene’s global clinical development strategy for detalimogene, as well as any future clinical development programs.
About enGene:
enGene is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs.
Contact:
No contact information was included in the press release.
Source: enGene
